Post Profile






Nivolumab reduces symptoms in relapsed metastatic head and neck cancer

(European Society for Medical Oncology) Nivolumab maintains function and reduces symptoms in treatment of relapsed metastatic head and neck cancer, according to results from the CheckMate 141 trial presented at the ESMO 2016 Congress in Copenhagen1 and published in the New England Journal of Medicine.
read more

share

Related Posts


Biothera To Present Research Results At European Society For Medical Oncology World Gastrointestinal Congress

Health : Medical News Today

Biothera has been accepted to present data from its Phase II clinical trial in stage IV KRAS-mutant colorectal cancer at the European Society for Medical Oncology (ESMO) 13th World Congress on Gastrointestinal Cancer June 22-25 in B...

Merck KGaA: Erbitux - First Treatment In 30 Years To Prolong Survival In 1st-Line Recurrent And/Or Metastatic Head And Neck Cancer

Health : Medical News Today

Data presented at the 33rd European Society for Medical Oncology (ESMO) Congress in Stockholm demonstrate that the addition of Erbitux® (cetuximab) to platinum-based chemotherapy increases overall survival (OS) compared to chemother...

Immunotherapy drug a 'gamechanger' for head and neck cancer

Health : The Guardian: Health

Nivolumab found to extend lives of relapsed patients who had run out of therapy options An immunotherapy drug hailed as a potential “gamechanger” in the treatment of cancer could soon offer new hope to patients with currently untrea...

Immunotherapy: Promising results in first & second line treatment of metastatic bladder cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) Immunotherapy has shown promising results in first and second line treatment of metastatic bladder cancer in two phase II trials presented at the ESMO 2016 Congress in Copenhagen.

Nivolumab maintains function, reduces symptoms in treatment of relapsed metastatic head and neck cancer

Diseases & Conditions / Cancer : ScienceDaily: Cancer

Nivolumab maintains function and reduces symptoms in treatment of relapsed metastatic head and neck cancer, according to results from the CheckMate 141 trial.

Comments


Copyright © 2016 Regator, LLC